In a significant development, Novartis announced on Tuesday (September 26, 2023) that its forthcoming generic-drugs division, Sandoz, has secured approval from the European Commission for Tyruko (natalizumab). This drug is designed to address relapsing forms of multiple sclerosis.
Tyruko marks a pioneering milestone as the first biosimilar for the treatment of multiple sclerosis in Europe. Novartis confirmed in a statement that it has received approval for all indications of the reference medicine.
